Annexon, Inc. (NASDAQ:ANNX) Short Interest Up 27.4% in June

Annexon, Inc. (NASDAQ:ANNX) was the target of a large increase in short interest in June. As of June 30th, there was short interest totalling 5,160,000 shares, an increase of 27.4% from the June 15th total of 4,050,000 shares. Based on an average daily volume of 2,820,000 shares, the days-to-cover ratio is presently 1.8 days.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. BVF Inc. IL acquired a new position in Annexon during the fourth quarter worth $31,780,000. Bain Capital Life Sciences Investors LLC raised its holdings in shares of Annexon by 41.4% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 8,061,719 shares of the company’s stock valued at $36,600,000 after purchasing an additional 2,359,793 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Annexon in the fourth quarter valued at about $221,000. SG Americas Securities LLC raised its holdings in shares of Annexon by 14.1% in the fourth quarter. SG Americas Securities LLC now owns 25,335 shares of the company’s stock valued at $115,000 after purchasing an additional 3,123 shares during the last quarter. Finally, Lighthouse Investment Partners LLC purchased a new stake in shares of Annexon in the fourth quarter valued at about $306,000.

Annexon Stock Performance

NASDAQ:ANNX opened at $6.17 on Tuesday. The firm’s fifty day moving average is $5.08 and its 200-day moving average is $5.17. Annexon has a 52 week low of $1.57 and a 52 week high of $8.40. The firm has a market cap of $570.19 million, a P/E ratio of -4.20 and a beta of 1.29.

Annexon (NASDAQ:ANNX) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.11. As a group, sell-side analysts anticipate that Annexon will post -0.98 earnings per share for the current year.

Analysts Set New Price Targets

ANNX has been the subject of a number of research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research report on Wednesday, June 5th. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Annexon in a report on Tuesday, June 4th. Bank of America boosted their target price on shares of Annexon from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, March 28th. JPMorgan Chase & Co. boosted their target price on shares of Annexon from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Monday, April 1st. Finally, Wells Fargo & Company reduced their target price on shares of Annexon from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, May 15th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $15.33.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.